Hunton Andrews Kurth Continues Global Energy Team Expansion in London
11.12.2024 10:00:00 CET | Business Wire | Press release
One Year of Sustained Local Growth Includes More Than Two Dozen Lawyers
Hunton Andrews Kurth LLP continues to expand in London with the addition of nearly a dozen highly regarded energy and project finance lawyers.
Partners Charles Morrison, Dimitri Papaefstratiou, Simon Collier, Harry Brunt, Counsel Joseph Lam, and ConsultantGrant Henderson, along with five associates, have joined the firm from Ernst & Young’s legal services arm, EY Law. The team focuses on transactions in various energy sectors, such as oil and gas, renewable and thermal power, as well as emerging technologies of carbon capture, hydrogen and energy storage.
“The addition of these distinguished lawyers underscores our commitment to maintaining our position as a leading adviser to the global energy industry,” said Hunton Andrews Kurth Managing Partner Sam Danon. “The team aligns well with our international growth strategy, which is focused on ensuring that we’ve achieved critical mass in key practices, in core industry focus areas and in geographies where client demand is strong.”
“Energy sector activity remains incredibly robust, driven by the need for renewable and alternative solutions in support of the energy transition as well as the need for infrastructure and traditional resource development in emerging and mature economies,” added Jeff Schroeder, head of Hunton Andrews Kurth’s energy and infrastructure team. “We are particularly excited about the team’s capabilities to grow the pipeline of complex, cross-border energy projects and adding depth to our global energy practice.”
In support of its international growth strategy, since August 2023, Hunton Andrews Kurth has added more than two dozen lawyers to its London office. Most recently, finance Partners Alan Cunningham and Richard Skipper joined the firm from EY Law. In September, the firm added project finance Partners Ayesha Waheed and Seyfi Can Kandemir. Last year, Hunton Andrews Kurth welcomed to Londoncorporate energy Partner Philip Mace and energy and infrastructure disputes Partners Maurice Kentonand David Hesse, Counsel Edward Hamiltonand Special Counsel Simon Schooling, who collectively are leading members of the firm’s international arbitration team.
“Our energy-focused corporate and disputes teams in London have experienced tremendous growth over the past year, expanding our reach throughout Europe, the Middle East and Africa,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are pleased to welcome our newest colleagues to the firm.”
About Hunton Andrews Kurth’s Energy and Infrastructure Team
Hunton Andrews Kurth’s global energy and infrastructure lawyers assist clients in bringing some of the world’s largest and most complex projects to market. Our team provides concept-to-close advice on the development and financing of capital-intensive projects. We represent sponsors, lenders, investors, governments, and other project participants operating in virtually every segment of the energy industry and infrastructure industry. Our projects attorneys have handled transactions in more than 75 countries, with market leading strengths in project finance, agency finance, commercial nuclear power, U.S. energy tax credits, subsea fiber-optic networks, and utility capital markets, among many others.
About Hunton Andrews Kurth LLP
For more than 120 years, Hunton Andrews Kurth has served clients across the globe with a collaborative and purposeful approach. With offices strategically located in the United States and around the world, the firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable depth across numerous practice areas. Hunton Andrews Kurth fosters a strong culture built upon an unwavering commitment to its clients, colleagues, and communities. To learn more, please visit huntonak.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211423314/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom